Zura Bio (NASDAQ:ZURA) Price Target Cut to $10.00 by Analysts at Chardan Capital

Zura Bio (NASDAQ:ZURA - Get Free Report) had its target price dropped by equities research analysts at Chardan Capital from $12.00 to $10.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Chardan Capital also issued estimates for Zura Bio's FY2025 earnings at ($0.77) EPS and FY2026 earnings at ($0.78) EPS.

A number of other analysts also recently issued reports on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a research report on Wednesday, December 11th. HC Wainwright restated a "neutral" rating and issued a $5.00 price target on shares of Zura Bio in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Zura Bio has a consensus rating of "Buy" and a consensus price target of $15.00.

Zura Bio Stock Performance

Shares of ZURA traded down $0.09 during midday trading on Wednesday, hitting $1.27. 218,258 shares of the company traded hands, compared to its average volume of 377,376. The stock has a market cap of $82.60 million, a price-to-earnings ratio of -2.39 and a beta of 0.06. The firm has a 50 day moving average of $1.46 and a 200-day moving average of $2.73. Zura Bio has a 52 week low of $1.07 and a 52 week high of $6.35.

Remove Ads

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. The firm had revenue of $0.00 million for the quarter. Sell-side analysts predict that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in shares of Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock worth $6,583,000 after acquiring an additional 2,611,532 shares in the last quarter. Braidwell LP acquired a new stake in Zura Bio in the third quarter valued at approximately $10,040,000. Sphera Funds Management LTD. purchased a new position in shares of Zura Bio during the 3rd quarter valued at approximately $2,999,000. Millennium Management LLC increased its holdings in Zura Bio by 1,499.0% in the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company's stock worth $1,753,000 after acquiring an additional 657,420 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Zura Bio by 70.6% during the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock worth $3,706,000 after acquiring an additional 377,545 shares during the period. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.